# Resverlogix Corp

Organization · id `cardio:org-resverlogix-corp` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Resverlogix+Corp>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Resverlogix Corp
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (`cardio:ct-nct01067820`)
- Sponsors: The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation (`cardio:ct-nct01423188`)
- Sponsors: Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD (`cardio:ct-nct02586155`)

## Provenance

Content hash: 5c8b97c27115e69e449d7cbc67497a060d2f88eac56599be7de2f604b849db80
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
